Strategic Growth Publicly traded biopharma with multiple oncology and IPF/asthma preclinical programs, presenting cross-indication sales opportunities through licensing, partnerships, or co-development deals with larger biotech or pharma firms seeking early-stage asset expansion.

Platform Leverage Two proprietary platforms (tumor-targeting toxin and NeoLipid liposomal delivery) create selling points for collaboration or contract manufacturing opportunities, as well as potential for out-licensing library assets to accelerate partner drug development.

Clinical Portfolio Five drug candidates in various clinical/preclinical stages signal near-term inflection points for milestone-driven partnerships, out-licensing negotiations, or strategic investments around key trial milestones and data readouts.

Regional Presence Lake Bluff, Illinois operations plus a history of expansion into international markets (evidenced by claims of rapid growth in Bulgaria) suggest opportunities to pursue regional commercialization collaborations, distribution deals, or contract services with global distributors.

Market Readiness OTC listing and revenue range indicate mid-market trajectory with potential for channel partnerships, co-promotion arrangements, or targeted outreach to mid-size distributors and specialty pharma networks looking to add oncology and fibrosis-focused assets.